Medlab Clinical Limited, a biotechnology company, researches, develops, and commercializes pharmaceutical and nutraceutical products in Australia. Its lead drug candidate includes NanaBis, an oro?buccal administered equimolar tetrahydrocannabinol (THC) and cannabidiol (CBD) formulation as monotherapy, which is in phase 3 multi-centre, quadruple-blind, randomized- withdrawal active, and placebo-controlled clinical study for the management of opioid-requiring?bone?pain due to metastatic cancer. The company also develops NanoCelle, a patented sub-micron drug delivery platform that enhances drug solubility issues and enables faster absorption and metabolism of active ingredients. In addition, it offers vitamins and supplements; and virtual clinic services. Medlab Clinical Limited was founded in 2012 and is headquartered in Botany, Australia.
| Market Capitalization | $35.9285 million |
| P/E Ratio | |
| P/E Growth Ratio | |
| Book Value | 0.036 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.031 |
| EBITDA | -8,283.301 |
| Profit Margin | -2.2547 |
| Operating Margin TTM | -2.6742 |
| Return on Assets TTM | -0.5027 |
| Return on Equity TTM | -1.2116 |
| Revenue TTM | 4,472.752 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2001-06-30 | 424,662 | 414,936 | 9,726 | 435,882 |
| 2006-06-30 | 611,934 | 342,030 | 269,904 | 589,671 |
| 2007-06-30 | 1,017,229 | 588,639 | 428,590 | 957,010 |
| 2008-06-30 | 1,445,827 | 780,797 | 665,030 | 1,344,667 |
| 2014-12-31 | 28 | 16 | 64.016 | 2,808.182 |
| 2015-06-30 | 1,266.16 | 100.66 | 1,165.5 | 4,426.516 |
| 2016-06-30 | 1,721.14 | 862.955 | 858.185 | 5,461.834 |
| 2017-06-30 | 3,290.926 | 1,725.322 | 1,565.604 | 6,543.248 |
| 2018-06-30 | 4,139.455 | 2,017.88 | 2,121.575 | 8,231.76 |
| 2019-06-30 | 5,431.976 | 3,063.663 | 2,368.313 | 13,117.421 |
| 2020-06-30 | 2,848.395 | 2,804.877 | 43.518 | 16,299.966 |
| 2021-06-30 | 4,399.412 | 2,939.794 | 1,459.618 | 17,448.619 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2006-06-30 | 92,420 | 275,752 | 175,385 | 11,529 | 70,765 | |
| 2007-06-30 | 168,488 | 397,175 | 252,831 | 9,772 | 70,765 | |
| 2008-06-30 | 243,025 | 541,482 | 345,373 | 6,540 | 70,765 | |
| 2014-12-31 | 1,080 | 2,934 | 575 | 241.635 | 241 | 5,252 |
| 2015-06-30 | 9,179.813 | 11,033.603 | 575.473 | 0.244 | 245.606 | 13,352.374 |
| 2016-06-30 | 801.368 | 3,265.971 | 1,374.307 | 19.528 | 253.048 | 10,611.41 |
| 2017-06-30 | 1,497.6 | 4,697.554 | 1,647.065 | 32.267 | 264.454 | 15,598.42 |
| 2018-06-30 | 20,332.694 | 24,326.972 | 2,468.409 | 499.703 | 39,163.42 | |
| 2019-06-30 | 11,441.975 | 20,204.377 | 5,211.725 | 971.976 | 41,621.32 | |
| 2020-06-30 | 9,063.044 | 17,788.523 | 6,533.232 | 704.03 | 51,361.909 | |
| 2021-06-30 | 13,434.762 | 20,646.306 | 5,740.453 | 705.9 | 66,811.113 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2001-06-30 | -7,864 | 43,794 | 614 | -3,352 | ||
| 2006-06-30 | 11,156 | 94,591 | 59,523 | -3,300 | ||
| 2007-06-30 | 50,229 | 133,723 | 76,068 | -3,300 | ||
| 2008-06-30 | 73,538 | 162,028 | 74,537 | -17,615 | ||
| 2014-12-31 | -2,420.603 | -3,291.971 | 1,135.622 | |||
| 2015-06-30 | -3,045.294 | -3,965.6 | -206.92 | 115.815 | ||
| 2016-06-30 | -3,493.083 | -3,896.83 | 685.553 | 115.815 | 801.368 | |
| 2017-06-30 | -3,657.644 | -4,262.877 | 696.232 | 801.368 | 1,497.6 | |
| 2018-06-30 | -4,570.395 | -4,775.366 | 18,835.094 | 1,497.6 | 20,332.694 | |
| 2019-06-30 | -8,090.937 | -10,316.577 | -8,890.719 | 20,332.694 | 11,441.975 | |
| 2020-06-30 | -13,399.374 | -10,422.42 | -2,378.931 | 11,441.975 | 9,063.044 | |
| 2021-06-30 | -12,323.705 | -10,352.966 | 4,371.718 | 9,063.044 | 13,434.762 |